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HIV
I Human Immunodeficiency Virus (HIV) is a retrovirus at the
source of the Acquired Immune Defficiency Syndrome (AIDS)
I HIV particles target cells of the immune system (mostly CD4+
lymphocytes and macrophages)
I Inclusion of HIV particles in immune cells lead to massive
production of new viral particles, death of the infected cells
and, ultimately, devastation of the immune system
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Current anti-HIV drugs
Two main categories:
1. Reverse Transcriptaese Inhibitors (RTI)
2. Protease Inhibitor (PI)
Figure: Taken from http://www.cellsalive.com/hiv0.htm
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Treatments for infected patients
I Highly Active Anti-Retroviral Therapy (HAART): combination
of two or more drugs. Usually one or more RTIs in
combinations with a PI.
I Two main concerns about the long-term used of anti retroviral
drugs: undesirable side effects (leading to poor compliance)
and mutation of the virus (need to change drugs or even
inability to find appropriate pharmaceutical treatments).
I Need for efficient drug scheduling strategies.
I Idealistically, a drug-scheduling strategy should bring the
system to a state where the immune system has control over
the virus (with low amount of drugs and low systemic effects).
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Structured Treatment Interruption (STI)
I STI: to cycle the patient on and off drug therapy
I STI strategies often well received by patients since they offer
them period of relief from treatment
I In some remarkable cases, STI strategies have enabled the
patients to maintain immune control over the virus in the
absence of treatment
Goal of this research: to compute optimal STI strategies
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STI: A glimpse at today’s practice
If CD4+ cell count falls below a certain threshold, put the patient
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More advanced techniques (not clinically tested)
I Some authors have proposed to design STI treatments by
exploiting mathematical models of the HIV infection.
I Models are under the form of a set of Ordinary Differential
Equations (ODEs)
I Deduction of STI strategies is done by using methods from
the control theory.
But modelling of the HIV dynamics is a difficult task. Indeed, one
has
I to select the right parametric system of ODEs
I to fit the parameters to reflect quantitatively biological
observations
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An interesting alternative
I Infer directly from clinical data good STI strategies, without
modelling the HIV infection dynamics.
I Clinical data: time evolution of patient’s state (CD4+ T cell
count, systemic costs of the drugs, etc) recorded at
discrete-time instant and sequence of drugs administered.
I Clinical data can be seen as trajectories of the immune system
responding to treatment.
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Inferring policies from trajectories
I Problem of inferring from trajectories appropriate control
policy has been studied in control theory and computer
science.
I One way to approach it: state an optimality criterion and
search for strategies optimizing this criterion.
I Classical approach: infer a model and derive from it and the
optimality criterion an optimal strategy.
I Reinforcement learning approach: compute optimal strategies
directly from the trajectory, without identifying a model.
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The trajectories are processed




problem which typically containts the following information:
some (near) optimal STI strategies,
often under the form of a mapping
given time and the drugs he has to take
protocols and are monitored at regular intervals
The patients follow some (possibly suboptimal) STI
The monitoring of each patient generates a trajectory for the optimal STI
drugs taken by the patient between t0 and t1 = t0 + n days
state of the patient at time t0
state of the patient at time t1
drugs taken by the patient between t1 and t2 = t1 + n days
state of the patient at time t2
drugs taken by the patient between t2 and t3 = t2 + n days
Processing of the trajectories gives
between the state of the patient at a
till the next time his state is monitored.
Figure: Determination of optimal STI strategies from clinical data by
using reinforcement learning algorithms: the overall principle.
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Learning from a sample of trajectories: the RL approach
Problem formulation
Discrete-time dynamics:
xt+1 = f (xt , ut) t = 0, 1, . . .
where xt ∈ X and ut ∈ U.
Cost function: c(x , u) : X × U → R. c(x , u) bounded by Bc .
Discounted infinite horizon cost associated to stationary policy





Optimal stationary policy µ∗ : Policy that minimizes Jµ for all x .
Objective: Find an optimal policy µ∗.
We do not know: The discrete-time dynamics.
We know instead: A set of trajectories (x0, u0, x1, · · · , uT−1, xT ).
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Some dynamic programming results
Sequence of functions QN : X × U → R
QN(x , u) = c(x , u) + γ min
u′∈U
QN−1(f (x , u), u
′), ∀N > 1
with Q1(x , u) ≡ c(x , u), converges to the Q-function, unique
solution of the Bellman equation:
Q(x , u) = c(x , u) + γ min
u′∈U
Q(f (x , u), u′).
Necessary and sufficient optimality condition:
µ∗(x) ∈ arg min
u∈U
Q(x , u)
Stationary policy µ∗N :
µ∗N(x) ∈ arg min
u∈U
QN(x , u).
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Fitted Q iteration
Trajectories (x0, u0, x1, · · · , uT−1, xT ) transformed into a set of







Fitted Q iteration computes from F the functions Qˆ1, Qˆ2, . . .,
QˆN , approximations of Q1, Q2, . . ., QN .
Computation done iteratively by solving a sequence of standard
supervised learning (SL) problems. Training sample for the k th
(k ≥ 2) problem is{(














Qˆ1(x , u) ≡ c(x , u). From the k
th training sample, the supervised
learning algorithm outputs Qˆk .
µˆ∗N(x) ∈ arg min
u∈U
QˆN(x , u) is taken as approximation of µ
∗(x).
In our simulations, SL method used is an ensemble of regression
trees method named Extra-Trees.
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Illustration
I We present results we have obtained by using the RL-based
approach on artificially generated data.
I The example is directly inspired from
B.M. Adams, H.T. Banks, Hee-Dae Kwon and H.T. Tran.
(2004). “Dynamic multidrug therapies for HIV: Optimal and
STI Control Approaches”. Mathematical Biosciences and
Engineering, 1, 223-241.
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Illustration: Kinds of STI strategies targeted
Bi-therapy treatments combining a fixed RTI and a fixed PI.
Revise drug administration every five days based on clinical
measurements.
Four possible on-off combinations for the next five days: RTI and
PI on, only RTI on, only STI on, RTI and PI off
We seek STI strategies that minimize Jµ.
Instantaneous cost at time t:





1t = 0.7 (resp. 1t = 0) if the RTI is cycled on (resp. off) at t
2t = 0.3 (resp. 2t = 0) if the PI is cycled on (resp. off) at time t
V : number of free HI viruses
E : number of cytotoxic T -lymphocytes
Decay factor γ: chosen equal to 0.98.
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Illustration: A mathematical model as substitute for
real-life patients
T˙1 = λ1 − d1T1 − (1− 1)k1VT1
T˙2 = λ2 − d2T2 − (1− f 1)k2VT2
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2 ) = non-infected (infected) macrophages
V = number of free HI viruses
E = number of cytotoxic T -lymphocytes.
1 and 2 = control actions corresponding to RTI and the PI.
Period during which the RTI (resp. the PI) is administrated to the
patient: 1 (resp. 2) is set equal to 0.7 (resp. 0.3).
RTI (resp. the PI) not administrated: 1 = 0 (resp. 2 = 0).
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Illustration: Some insight into this model






2 ,V ,E ) = (10
6, 3198, 0, 0, 0, 10)





2 , V , E ) = (967839, 621, 76, 6, 415, 353108)
(small viral load, a high CD4+ T-lymphocytes count, high
HIV-specific cytotoxic T-cells count)





2 , V , E ) = (163573, 5, 11945, 46, 63919, 24)
(T-cells depleted, viral load very high).
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Illustration: Protocol for artificially generating the clinical
data
Monitoring of patients: every five days during 1000 days.
Medication: can be revised every five days based on the
information generated by the monitoring.
Iterative generation of the clinical data (ten iterations):
I First iteration. Thirty patients in “non-healthy” steady-state.




2 , V , E ) recorded and a
new type of medication randomly selected in U every five
days. Monitoring of each patient generates a trajectory
(x0, u0, x1, · · · , x199, u199, x200).
I Second iteration. Only difference with first iteration:
medication determined by the following STI strategy: in 85%
of the cases, use strategy µˆ∗400 computed by fitted Q iteration
on previously generated trajectories; in the remaining 15%
medication randomly selected in U.
I Third-tenth iteration: idem as second iteration.




































































































Figure: Solid curve (−) corresponds = patient which follows STI
strategies; dashed curves (−−) = no interruption in the treatment;
dotted curves (− ·) = no treatment








































Figure: STI treatment for a patient treated from early stage of infection.













Figure: Influence of the number of patients on the infinite time horizon
cost corresponding to the computed STI strategies.
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From numerically simulated data to real-life patients
We expect to face four main difficulties:
I The HIV/immune system dynamics may be different from one
patient to the other.
I Difficulty to state properly the optimal control problem
I Partial observability
I Corrupted measurements
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Conclusions
I Reinforcement learning algorithms seem to be promising tools
to extract from clinical data, good STI strategies.
I Lot of work is however still needed !!!
I But 40 millions of people are living with HIV/AIDS. Isn’t it a
good reason to keep working hard ?
Figure: Taken from UNAIDS. AIDS epidemic update: December 2005.
“UNAIDS/05.19E”
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